Valuation: Healios K.K.

Market Cap 35.64B 220M 193M 178M 164M 310M 21.02B 316M 2.13B 834M 10.32B 824M 806M P/E 2026 *
-7.25x
P/E 2027 * -12.9x
Enterprise Value 35.38B 218M 191M 177M 163M 308M 20.86B 314M 2.11B 828M 10.24B 818M 801M EV / Sales 2026 *
58.8x
EV / Sales 2027 * 4.07x
Free-Float
77.9%
Yield 2026 *
-
Yield 2027 * -
1 day+1.15%
1 week+5.60%
Current month+4.35%
1 month+1.15%
3 months-28.07%
6 months-3.30%
Current year-3.65%
1 week 235
Extreme 235
272
1 month 235
Extreme 235
281
Current year 234
Extreme 234
483
1 year 234
Extreme 234
747
3 years 114
Extreme 114
747
5 years 114
Extreme 114
2,557
10 years 114
Extreme 114
2,557
Manager TitleAgeSince
Chief Executive Officer 49 2018-02-28
Director of Finance/CFO 49 2019-07-15
Chief Tech/Sci/R&D Officer - 2025-12-31
Director TitleAgeSince
Director/Board Member 49 2012-01-31
Director/Board Member 49 2018-02-28
Director/Board Member 72 2018-02-28
Change 5-day change 1-year change 3-year change Capi.($)
+1.15%+5.60%-48.94%-18.77% 218M
-2.48%-3.13%+55.85%+89.65% 54.88B
-0.55%-8.57%+58.09%+124.47% 54.63B
-5.60%-2.15%+7.12%+420.46% 25.06B
-1.55%-4.11%-18.86%-17.75% 23.14B
-1.69%-0.64%+40.04%-0.48% 19.87B
+1.87%+4.16%+38.74%-26.42% 17.55B
-2.72%-0.60%+187.08%+351.91% 16.5B
-2.42%+1.00%+48.24%+635.77% 15.75B
-0.81%+0.92%+22.95%+189.61% 14.2B
Average -1.43%-0.30%+39.03%+174.84% 24.18B
Weighted average by Cap. -1.76%-1.56%+48.05%+164.94%

Financials

2026 *2027 *
Net sales 602M 3.71M 3.25M 3.01M 2.77M 5.24M 355M 5.35M 35.92M 14.09M 174M 13.93M 13.63M 9.12B 56.18M 49.27M 45.64M 41.99M 79.42M 5.38B 80.97M 544M 213M 2.64B 211M 206M
Net income -4.77B -29.39M -25.78M -23.88M -21.97M -41.55M -2.81B -42.36M -285M -112M -1.38B -110M -108M -2.94B -18.14M -15.91M -14.74M -13.56M -25.65M -1.74B -26.15M -176M -68.89M -853M -68.12M -66.63M
Net Debt -260M -1.6M -1.4M -1.3M -1.2M -2.26M -153M -2.31M -15.5M -6.08M -75.23M -6.01M -5.88M 1.46B 9.01M 7.91M 7.32M 6.74M 12.74M 863M 12.99M 87.27M 34.23M 424M 33.84M 33.11M
Logo Healios K.K.
Healios KK is a Japan-based company mainly engaged in business in the somatic stem cell regenerative medicine field and in the iPSC regenerative medicine field, which involves research, development and manufacture of regenerative medicine products (iPSC regenerative medicines) utilizing technologies related to induced pluripotent stem cells (iPS cells, iPSCs). The somatic stem cell regenerative medicine field develops and markets cell therapy drugs for acute stroke and acute respiratory distress syndrome using MultiStem, a somatic stem cell product for which the Company holds patent and patent licensing rights. The iPSC regenerative medicines include the creation of universal donor cells (UD), next-generation iPSCs that reduce the risk of immune rejection regardless of human leukocyte antigen (HLA) type using gene editing technology.
Employees
75
Date Price Change Volume
26-07-13 JP¥264.00 +1.15% 1,229,000
26-07-10 JP¥261.00 +1.95% 2,199,900
26-07-09 JP¥256.00 +7.56% 2,560,200
26-07-08 JP¥238.00 -1.24% 1,250,700
26-07-07 JP¥241.00 -4.37% 2,146,000
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
264.00JPY
Average target price
779.83JPY
Spread / Average Target
+195.39%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4593 Stock